



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Sunitinib in Advanced or Metastatic Renal Cell
Carcinoma (RCC)**

Approved Use:

Sunitinib: As a **single agent first line treatment** in patients with documented evidence of histologically confirmed advanced or metastatic clear cell RCC who have an ECOG performance status of 0 or 1. In any one patient, all of the following conditions must be met:

1. Sunitinib may be a first line option.
 2. Sunitinib may not be used after another tyrosine kinase inhibitor (i.e. sorafenib) as sequential therapy.
 3. In the event of severe toxicity within the first 8 weeks of therapy, a switch to another tyrosine kinase inhibitor (i.e. sorafenib) may be allowed.
- This policy recommendation represents a **new guideline document** and a restriction of sunitinib to include advanced or metastatic RCC patients as a first line therapy option.

Approved by: _____

Date: _____